Use of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY

Diabetes Care. 2024 Sep 1;47(9):e65-e66. doi: 10.2337/dc24-0730.

Authors

David T Broome¹, Alina Mehdi¹, Colby Chase², Maria Foss de Freitas¹, Brigid E Gregg¹, Elif A Oral¹, William H Herman¹

Affiliations

¹ Division of Internal Medicine, Department of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI.
² Department of Human Genetics, University of Michigan, Ann Arbor, MI.

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Adult
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / genetics
Female
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide-1 Receptor* / agonists
Hepatocyte Nuclear Factor 1-alpha* / genetics
Hepatocyte Nuclear Factor 4* / genetics
Humans
Middle Aged
Receptors, Gastrointestinal Hormone / agonists
Receptors, Gastrointestinal Hormone / genetics

Substances

Gastric Inhibitory Polypeptide
gastric inhibitory polypeptide receptor
Glucagon-Like Peptide-1 Receptor
Hepatocyte Nuclear Factor 1-alpha
Hepatocyte Nuclear Factor 4
HNF1A protein, human
HNF4A protein, human
Receptors, Gastrointestinal Hormone

Grants and funding